BackgroundCheck.run
Search For

Edward S Wei, 4610 47Th St, New York, NY 10036

Known as:
Ed Wei
Related to:
David Chanwook Lee 44 Rosemary N Ng 66

Edward Wei Phones & Addresses

10 47Th St, New York, NY 10036    212-7191345   

271 W 47Th St APT 41B, New York, NY 10036    212-2479491   

San Francisco, CA   

Cambridge, MA   

Washington, DC   

2634 46Th Ave, San Francisco, CA 94116   

Work

Company: TUFTS MEDICAL CENTER DEPARTMENT OF PHYSICAL MEDICINE & REHABILITATION Address: 800 Washington St Suite 400, Boston, MA 02111 Phones: 617-6365625 (Phone) 617-6365000 (Fax)

Education

School / High School: Harvard

Languages

English

Ranks

Licence: New York - Currently registered Date: 2006
Get Report
Control this profile

Mentions for Edward S Wei

Career records & work history

Lawyers & Attorneys

Edward Wei Photo 1

Edward S. Wei, New York NY - Lawyer

Address:
Cadwalader, Wickersham & Taft
1 World Financial Ctr, New York, NY 10281
212-5046799 (Office)
Licenses:
New York - Currently registered 2006
Education:
Harvard
Specialties:
Tax - 34%
Corporate / Incorporation - 33%
Antitrust / Trade Law - 33%

Medicine Doctors

Edward Wei Photo 2

Dr. Edward Wei, Boston MA - MD (Doctor of Medicine)

Specialties:
Internal Medicine
Address:
TUFTS MEDICAL CENTER DEPARTMENT OF PHYSICAL MEDICINE & REHABILITATION
800 Washington St Suite 400, Boston, MA 02111
617-6365625 (Phone) 617-6365000 (Fax)
Languages:
English

Edward Wei

Specialties:
Physical Medicine & Rehabilitation
Work:
Tufts Floating Hospital For Children Physical Medicine & Rehabilitation
800 Washington St STE 415, Boston, MA 02111
617-6365626 (phone) 617-6365056 (fax)
Education:
Medical School
UMDNJ New Jersey Medical School at Newark
Graduated: 2012
Languages:
English
Description:
Dr. Wei graduated from the UMDNJ New Jersey Medical School at Newark in 2012. He works in Boston, MA and specializes in Physical Medicine & Rehabilitation. Dr. Wei is affiliated with Floating Hospital For Children At Tufts Medical Center and Tufts Medical Center.
Edward Wei Photo 3

Edward Wei

Specialties:
Internal Medicine

Edward Wei resumes & CV records

Resumes

Edward Wei Photo 38

Software Engineer

Location:
500 Fulton St, Palo Alto, CA 94301
Industry:
Computer Software
Work:
Oculus Vr
Software Engineer Highfive Dec 2014 - Apr 2018
Staff Engineer Highfive Aug 2012 - Apr 2018
Founding Software Engineer Jawbone May 2011 - Aug 2012
Senior Software Engineer Opelin Jul 2010 - May 2011
Senior Software Engineer Palm Jul 2005 - Jun 2010
Senior Software Engineer Lyric Theatre of San Jose 2006 - 2009
Chorus Opera San José 2006 - 2009
Chorus
Education:
Dartmouth College 2003 - 2005
Master of Science, Masters, Computer Science Dartmouth College 1999 - 2003
Bachelors, Bachelor of Arts, Computer Science
Skills:
Software Engineering, Embedded Systems, C, Device Drivers, Embedded Software, Linux Kernel, Debugging, Software Design, Embedded Linux, Software Development, Linux, Mobile Devices, Testing, C++, System Architecture, Algorithms, Distributed Systems, Git
Languages:
English
Edward Wei Photo 39

Partner

Location:
New York, NY
Industry:
Legal Services
Work:
Gibson, Dunn & Crutcher Llp
Partner Cadwalader, Wickersham & Taft Llp Apr 2011 - May 2019
Partner Cravath, Swaine & Moore Llp Feb 2006 - Feb 2011
Associate
Education:
University of Cambridge
Masters, Master of Laws Columbia University In the City of New York
Bachelors Harvard Law School
Doctor of Jurisprudence, Doctorates, Law
Skills:
Mergers and Acquisitions, Corporate Law, Tax Law, International Tax, Corporate Tax, Legal Writing, Real Estate, Private Equity

Publications & IP owners

Us Patents

1,2,3,6-Tetrahydropyrimidine-2-One Compositions And Therapeutic Methods Therewith For Pain And Inflammation

US Patent:
6743801, Jun 1, 2004
Filed:
Aug 29, 2002
Appl. No.:
10/232798
Inventors:
Edward T. Wei - Berkeley CA, 94708
International Classification:
A61K 31513
US Classification:
514269, 514345, 544318
Abstract:
A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.

Inhibition Of Abnormal Cell Growth With Corticotropin-Releasing Hormone Analogs

US Patent:
6803359, Oct 12, 2004
Filed:
Nov 19, 2001
Appl. No.:
09/997498
Inventors:
Edward T. Wei - Berkeley CA
Andrzej T. Slominski - Glen Ellyn IL
Assignee:
The Regents of the University of California - Oakland CA
Loyola University of Chicago - Maywood IL
International Classification:
C07K 1400
US Classification:
514 12, 530350, 530306, 530300
Abstract:
The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions in cell culture and inhibit experimental cancer growth in animals (mice and rats). Novel applications of such analogs are described, such as to inhibit abnormal cell proliferation for conditions such as cancer, including melanoma, and for inflammatory dermatoses, such as psoriasis.

Corticotropin-Releasing Hormone Analogs

US Patent:
6849600, Feb 1, 2005
Filed:
Mar 25, 2002
Appl. No.:
10/106588
Inventors:
Edward T. Wei - Berkeley CA, US
Kurt W. Carlson - Sausalito CA, US
Assignee:
The Regents of the University of California, Berkeley - Berkeley CA
International Classification:
A61K 3812
A61K 3817
C07K 1447
US Classification:
514 12, 514 2, 514 9, 530300, 530317, 530324, 930 21, 930270
Abstract:
This invention relates to peptide analogs of corticotropin-releasing hormone. Particularly, the invention provides analogs wherein the 38amino acid from the N-terminus is D-Nle, i. e. [D-Nle]-CRH peptide.

Compositions For Trp-M8 Binding And Radioreceptor Methods Therewith

US Patent:
6893626, May 17, 2005
Filed:
Feb 18, 2003
Appl. No.:
10/370483
Inventors:
Edward T. Wei - Berkeley CA, US
International Classification:
A61K051/00
US Classification:
424 181, 568 14
Abstract:
One embodiment of the invention is a composition that comprises a radioactive P or P phosphine oxide molecule. The said composition is designed to bind to the transient potential receptor-M8 (TRP-M8) receptor of cells. The radioactive P or P phosphine oxide ligand may be used for radioreceptor binding studies and for diagnostic studies of cancerous tissues. The TRP-M8 receptor is selectively expressed in malignant tissues such as prostate cancer cells. Affinity of the P or P phosphine oxide ligand for the TRP-M8 receptor confers selectively and specificity in delivering lethal radiation to the diseased cells.

Therapeutic 1,2,3,6-Tetrahydropyrimidine-2-One Compositions And Methods Therewith

US Patent:
6919348, Jul 19, 2005
Filed:
May 2, 2002
Appl. No.:
10/139193
Inventors:
Edward T. Wei - Berkeley CA, US
International Classification:
A61K031/513
A61K038/18
US Classification:
514269, 514345, 514318, 544318
Abstract:
A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an anti-histamine, a local anesthetic, menthol or a menthol analog, and mixtures thereof. The cold receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the anogenital areas, and to the enteric mucosa.

1,2,3,6-Tetrahydropyrimidine-2-One Compositions, Articles And Therapeutic Methods For Upper Airway Breathing Disorders

US Patent:
6933301, Aug 23, 2005
Filed:
Oct 8, 2002
Appl. No.:
10/267896
Inventors:
Edward T. Wei - Berkeley CA, US
International Classification:
A61K031/513
A61K038/18
A61K031/47
C07D241/40
C07D215/16
US Classification:
514269, 514345, 514311, 514312, 514313, 514314, 544318, 546153, 546159, 546171, 546178, 546179
Abstract:
A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount. The cold receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention when formulated for delivery to the mucous membranes of the nose and throat alleviate the sensations of airway obstruction and provide symptomatic relief of upper airway breathing disorders.

Melanocortin Receptor Antagonists And Modulations Of Melanocortin Receptor Activity

US Patent:
6953779, Oct 11, 2005
Filed:
May 4, 2001
Appl. No.:
09/849592
Inventors:
Edward T. Wei - Berkeley CA, US
J. Mark Quillan - Orleans, CA
Guennady P. Vlasov - Sankt Petersburg, RU
Jaw Kang Chang - San Carlos CA, US
International Classification:
A61K038/08
US Classification:
514 16, 514 2, 530329, 435325
Abstract:
The clinical outcome of disseminated melanoma is grim. Small molecular weight antagonists (preferably about seven amino acid residues) specific for MCR on melanoma cells are provided for the therapy of melanoma as well as in other conditions where modulation of MCR is of clinical significance. A particularly preferred antagonist is p-anisoyl-[D-Arg, D-Lys, D-Leu] dynorphin A(6-12)-NH, which is an excellent antagonist of the MCR-1 receptor.

Radioligands For The Trp-M8 Receptor And Methods Therewith

US Patent:
7169377, Jan 30, 2007
Filed:
Oct 15, 2003
Appl. No.:
10/687188
Inventors:
Edward T. Wei - Berkeley CA, US
International Classification:
A61K 51/00
A61M 36/14
US Classification:
424 189, 424 111, 424 165, 424 181, 424 185
Abstract:
One embodiment of the invention is a composition that comprises a radioactive [F], [I], [I], or [I]-N-radiohaloaryl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [F], [I], [I], or [I]-N-radiohaloaryl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the [I] or [I]-N-radiohaloaryl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.

Possible Relatives

Dawei D Wei  Dan Wei  Daniel K Wei  Dao C Wei  Dongsheng Wei  Eddie Y Wei  Ellen Y Wei  Edward M Johnson  Edward M Stan  Edward W Stanchak 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.